The only FDA-approved test for PD-L1 expression associated with enhanced survival with OPDIVO® (nivolumab) for non-squamous NSCLC.
PD-L1 IHC 28-8 pharmDx is a complementary diagnostic for PD-L1 expression in non-squamous NSCLC.
Patients with PD-L1 expression by all predefined expression levels in the OPDIVO group were associated with enhanced survival compared to docetaxel.
≥ 1% PD-L1 expression → 41% Reduction in Risk of Death (HR = 0.59) 17.1 months median OS vs. 9 months for docetaxel
≥ 5% PD-L1 expression → 57% Reduction in Risk of Death (HR = 0.43) 18.2 months median OS vs. 8.1 months for docetaxel
≥ 10% PD-L1 expression → 60% Reduction in Risk of Death (HR = 0.40) 19.4 months median OS vs. 8 months for docetaxel
PD-L1 testing is not required for the use of OPDIVO, but it will provide additional information for physicians and inform patient dialogue.
In patients with no PD-L1 expression (< 1%), survival with OPDIVO was similar to docetaxel.
Dako PD-L1 IHC 28-8 pharmDx is FDA approved and fully validated with analytical performance having met all pre-determined acceptance criteria for sensitivity, specificity and precision.
|Selected analytical validation parameters||Description|
* Negative Percent Agreement, Positive Percent Agreement, Overall Percent Agreement
Reference 2) Phillips T, Simmons P, Inzunza H, Cogswell J, Novotny J, Taylor C, Zhang X. Development of an automated PD-L1 immunohistochemistry (IHC) assay for non.small cell lung cancer. Appl Immunohistochem Mol Morph 2015;8:541-9.
|PD-L1 IHC 28-8 pharmDx||SK005|
Required but not included in kit:
Autostainer Link 48
EnVision FLEX Wash Buffer, 20x
EnVision FLEX Hematoxylin (Link)
Contact your local sales representative
Product details, specification sheet and safety data sheet (SDS).
For in vitro diagnostic use
PD-L1 IHC 28-8 pharmDx is a qualitative immunohistochemical assay using Monoclonal Rabbit Anti-PD-L1, Clone 28-8 intended for use in the detection of PD-L1 protein in formalin-fixed paraffin-embedded (FFPE) non-squamous non small cell lung cancer (NSCLC) and melanoma tissue using EnVision FLEX visualization system on Autostainer Link 48. PD-L1 protein expression is defined as the percentage of tumor cells exhibiting positive membrane staining at any intensity.
PD-L1 expression as detected by PD-L1 IHC 28-8 pharmDx in non-squamous NSCLC may be associated with enhanced survival from OPDIVO® (nivolumab) treatment.
Positive PD-L1 status as determined by PD-L1 IHC 28-8 pharmDx in melanoma is correlated with the magnitude of the treatment effect on progression-free survival from OPDIVO®.
Welcome To Agilent Technologies
To enhance your online experience and our partnership with you, please select your country from the lists below.This will ensure that you discover the most relevant information and services available, including local product news, events, and more.